Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 143-147

  Giordano, Paola ^a   Lassandro, Giuseppe ^a   Tesse, Riccardina ^a   Longo, Stefania ^b   Valente, Federica ^a   Cappiello, Anna Rita ^a   Coppola, Antonio ^c  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Children; Glanzmann's thromboasthenia; Prevention; Recombinant activated factor VII

Indexed keywords

PARACETAMOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHRALGIA; ARTICLE; BONE RADIOGRAPHY; CASE REPORT; CHILD; CHILDHOOD DISEASE; FOLLOW UP; FOOT EDEMA; GLANZMANN DISEASE; HUMAN; JOINT EFFUSION; JOINT SWELLING; MALE; PHYSIOTHERAPY; PRESCHOOL CHILD; SINGLE DRUG DOSE; TISSUE INJURY;

CHILD; FACTOR VIIA; HUMANS; INFANT; ITALY; MALE; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 84872244854     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0016-12     Document Type: Article

References (28)

1. Saxena R, Kannan M. Glanzmann's thromboasthenia: an overview. Clin Appl Thromb Hemost 2009; 15: 152-65.
2. D'Andrea G, Chetta M, Margaglione M. Inherited platelet disorders: thrombocytopenias and thrombocytopathies. Blood Transfus 2009; 7: 278-92.
3. Shapiro AD. Platelet function disorders. Hemophilia 2000; 6: 120-7. (Pubitemid 30468303)
4. Nurden AT. Glanzmann thromboasthenia. Orphanet J Rare Dis 2006; 1: 10.
5. Poon M-C. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thromboasthenia. Vasc Health Risk Manag 2007; 3: 655-64. (Pubitemid 350104121)
6. Di Minno G, Coppola A, Di Minno MN, Poon M-C. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009; 102: 1157-64.
7. Novo Nordisk Inc; NovoSeven® Coagulation Factor VIIa (recombinant). US prescribing information. [online]; Available at: http://www.novoseven.com . Accessed on 14/12/2010.
8. Poon-MC. The evidence of the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorder. Transfus Med Rev 2007; 21: 223-36.
9. Jansen NW, Roosendal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current issues. Br J Haematol 2008; 143: 632-40.
10. Croom KF, McCormack PL. Recombinant factor VIIa (Eptacog alfa). A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Biodrugs 2008; 22: 121-36. (Pubitemid 351414753)
11. Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus 2009; 7: 24-8.
12. Tengborn L, Peturson B. A patient with Glanzmann's thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2. (Pubitemid 26355365)
13. Poon M-C, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3.
14. Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81. (Pubitemid 36628341)
15. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004; 125: 95-6. (Pubitemid 38453288)
16. Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2006; 28: 653-8. (Pubitemid 44536045)
17. Poon M-C, d'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103. (Pubitemid 40186082)
18. Hong I, Stachnik J. Unlabeled uses of factor VIIa (recombinant) in pediatric patients. Am J Health-Syst Pharm 2010; 67: 1909-19.
19. George JN, Caen JP, Nurden AT. Glanzamann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95. (Pubitemid 20114873)
20. Toogeh G, Sharifian R, Lak M, et al. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004; 77: 198-9. (Pubitemid 39281870)
21. Furmaniak-Kazmierczak E, Cooke TD, Manuel R, et al. Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest 1994; 94: 472-80. (Pubitemid 24250972)
22. Murata M, Yudoh K, Masuko K. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis Cartilage 2008; 16: 279-86. (Pubitemid 351309189)
23. Blamey G, Forsyth A, Zourikian N, et al. Comprehensive elements of physiotherapy exercise program in haemophilia: a global prospective. Haemophilia 2010; 16: 136-45.
24. Morris S, Ridley S, Munro V, Christensen MC. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the United Kingdom. Anaesthesia 2007; 62: 43-52. (Pubitemid 44869637)
25. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101: 674-81.
26. Kerr R. Imaging of musculoskeletal complications of hemophilia. Semin Muscoloskelet Radiol 2003; 7: 127-36. (Pubitemid 37048096)
27. Zukotynski K, Jarrin J, Babyn PS, et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007; 13: 293-304. (Pubitemid 46746053)
28. Melchiorre D, Linari S, Innocenti M, et al. Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score. Haemophilia 2011; 17: 112-7.